The "China IVD Market Size, Share, Trends, Regulations, Reimbursement & Company Analysis - Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

China In-Vitro Diagnostics (IVD) market is likely to grow with double digit CAGR during the period 2018 - 2024. China represents one of the largest clinical laboratory markets in the Asia-Pacific region, and the fastest growing among the top ten IVD country markets.

With an aging population, a rapidly growing middle class and a government encouraging preventive care, China IVD market is slated to show substantial growth in the future. China's quickly aging population means the country is experiencing an explosion of chronic conditions such as diabetes, heart disease and cancer. All of these conditions can be diagnosed and monitored using IVD products.

Further, the average Chinese consumer is now willing and able to pay more for healthcare than a decade years ago. Hence, China has the potential for more dramatic growth in the future.

China IVD Market Segment Wise Analysis

• Immunoassay captures maximum share of the China IVD market.
• Clinical Chemistry holds the 2nd position in China IVD market being followed by Molecular Testing.
• The molecular testing market in China is expected to grow in double digits during the forecasted period.
• China SMBG market is dominated by foreign IVD companies such as Roche.
• Microbiology and Hematology segments are competing closely with each other to grab maximum share of the pie.

China IVD Market Company Analysis

• Roche captures maximum share of the China IVD market.
• Sysmex Corporation and Mindary Medical are other top two players in the China IVD market.
• Sysmex is expanding its business portfolio in China, such as by entering the immunochemistry field there in 2015.
• At present, many local players are present in China IVD market and their combined market share was over 47 percent in 2016.
• This is the 3rd edition report on China IVD Market. The report titled China IVD Market Size, Share, Trends, Regulations, Reimbursement & Company Analysis - Forecast to 2024 provides a comprehensive analysis of the China IVD Market.

China IVD Market - By Application Segments

1. Clinical Chemistry Market

2. Immunoassay Market

3. Hematology Market

4. Coagulation Market

5. Microbiology Market

6. Molecular Testing Market

7. Self Monitoring of Blood Glucose (SMBG) Market

8. Point of Care Testing (POCT) Market

China IVD Sales & Forecast - By Company

1. Roche Diagnostic

2. Abbott Laboratories

3. Sysmex Corporation

4. Mindray Medical International Limited

5. Shanghai Kehua Bio-Engineering Co. Ltd.

6. Others

Profiles of Private Clinical Labs and Diagnostic Services Companies in China

• Zhejiang Di'an Diagnostics Technology Co., Ltd
• ADICON Clinical Laboratories
• Guangzhou Kingmed Diagnostics Center Co. Ltd.
• Kindstar Global (Privately held)
• BGI-Shenzhen (Privately held)
• OriGene Technologies (Privately held)

Key Topics Covered:

1. Executive Summary

2. China IVD Market and Market Share Analysis (2007 - 2024)

3. China IVD - Segments Wise Market and Forecast (2007 - 2024)

4. Development Environment of Chinese IVD Industry

5. Profile of In-vitro Diagnostic Reagents Registration Control

6. Registration for In Vitro Diagnostic Reagents in China

7. Reimbursement of IVD Products in China

8. China IVD Market - Company Wise Sales Analysis (2010 - 2024)

9. Profiles of Select Private Clinical Labs and Diagnostic Services Companies

10. China IVD Industry Drivers

11. China IVD Industry Challenge

For more information about this report visit https://www.researchandmarkets.com/research/4p57bz/china_ivd_market?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180622005592/en/